HAEM5:Acute basophilic leukaemia: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) Undo revision 14799 by Bailey.Glen (talk) Tag: Undo |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Acute basophilic leukaemia}} | {{DISPLAYTITLE:Acute basophilic leukaemia}} | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours ( | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]] | ||
{{Under Construction}} | {{Under Construction}} | ||
| Line 7: | Line 7: | ||
}}</blockquote> | }}</blockquote> | ||
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples) | <span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span> | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
| Line 37: | Line 37: | ||
==Clinical Features== | ==Clinical Features== | ||
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table | Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span> | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Signs and Symptoms''' | |'''Signs and Symptoms''' | ||
| | |EXAMPLE Asymptomatic (incidental finding on complete blood counts) | ||
EXAMPLE B-symptoms (weight loss, fever, night sweats) | |||
EXAMPLE Fatigue | |||
EXAMPLE Lymphadenopathy (uncommon) | |||
|- | |- | ||
|'''Laboratory Findings''' | |'''Laboratory Findings''' | ||
| | |EXAMPLE Cytopenias | ||
EXAMPLE Lymphocytosis (low level) | |||
|} | |} | ||
<blockquote class='blockedit'>{{Box-round|title= | <blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}} | ||
Clinical features include bone marrow failure and may or may not have circulating blasts. Cutaneous involvement, oraganomegaly, lytic lesions and symptoms related to hyperhistanemia may be present<ref name=":0" />. | Clinical features include bone marrow failure and may or may not have circulating blasts. Cutaneous involvement, oraganomegaly, lytic lesions and symptoms related to hyperhistanemia may be present<ref name=":0" />. | ||
| Line 97: | Line 97: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC) | ||
EXAMPLE 30% (add reference) | |||
|Yes | |Yes | ||
|No | |No | ||
|Yes | |Yes | ||
| | |EXAMPLE | ||
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). | The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). | ||
| Line 108: | Line 108: | ||
<blockquote class='blockedit'>{{Box-round|title= | <blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}} | ||
No consistent chromosomal abnormalities have been reported in ABL due to its rarity<ref name=":3">Yenamandra A, et al., (2014). Acute basophilic leukemia, a rare subset of de novo AML with an abnormal tetraploid karyotype. JSM Cell Dev Biol 2(1):1007. Available online at <nowiki>https://www.academia.edu/28924195/Editorial_Article_Acute_Basophilic_Leukemia_a_Rare_Subset_of_De_Novo_AML_with_an_Abnormal_Tetraploid_Karyotype</nowiki>.</ref><ref name=":4">{{Cite journal|last=Dastugue|first=N.|last2=Duchayne|first2=E.|last3=Kuhlein|first3=E.|last4=Rubie|first4=H.|last5=Demur|first5=C.|last6=Aurich|first6=J.|last7=Robert|first7=A.|last8=Sie|first8=P.|date=1997|title=Acute basophilic leukaemia and translocation t(X;6)(p11;q23)|url=https://www.ncbi.nlm.nih.gov/pubmed/9233581|journal=British Journal of Haematology|volume=98|issue=1|pages=170–176|doi=10.1046/j.1365-2141.1997.1562968.x|issn=0007-1048|pmid=9233581}}</ref><ref name=":5">{{Cite journal|last=Quelen|first=Cathy|last2=Lippert|first2=Eric|last3=Struski|first3=Stephanie|last4=Demur|first4=Cécile|last5=Soler|first5=Gwendoline|last6=Prade|first6=Nais|last7=Delabesse|first7=Eric|last8=Broccardo|first8=Cyril|last9=Dastugue|first9=Nicole|date=2011|title=Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants|url=https://www.ncbi.nlm.nih.gov/pubmed/21474671|journal=Blood|volume=117|issue=21|pages=5719–5722|doi=10.1182/blood-2011-01-333013|issn=1528-0020|pmid=21474671}}</ref>. Rearrangement of MYB/GATA1 with t(X;6)(p11;q23) has been reported in four male infants<ref name=":4" /><ref name=":5" />. The fusion gene leads to downregulation of ''MYB'', upregulation of ''GATA1'', and commits myeloid cells to the granulocyte lineage and blocks their differentiation<ref name=":4" /><ref name=":5" />. | No consistent chromosomal abnormalities have been reported in ABL due to its rarity<ref name=":3">Yenamandra A, et al., (2014). Acute basophilic leukemia, a rare subset of de novo AML with an abnormal tetraploid karyotype. JSM Cell Dev Biol 2(1):1007. Available online at <nowiki>https://www.academia.edu/28924195/Editorial_Article_Acute_Basophilic_Leukemia_a_Rare_Subset_of_De_Novo_AML_with_an_Abnormal_Tetraploid_Karyotype</nowiki>.</ref><ref name=":4">{{Cite journal|last=Dastugue|first=N.|last2=Duchayne|first2=E.|last3=Kuhlein|first3=E.|last4=Rubie|first4=H.|last5=Demur|first5=C.|last6=Aurich|first6=J.|last7=Robert|first7=A.|last8=Sie|first8=P.|date=1997|title=Acute basophilic leukaemia and translocation t(X;6)(p11;q23)|url=https://www.ncbi.nlm.nih.gov/pubmed/9233581|journal=British Journal of Haematology|volume=98|issue=1|pages=170–176|doi=10.1046/j.1365-2141.1997.1562968.x|issn=0007-1048|pmid=9233581}}</ref><ref name=":5">{{Cite journal|last=Quelen|first=Cathy|last2=Lippert|first2=Eric|last3=Struski|first3=Stephanie|last4=Demur|first4=Cécile|last5=Soler|first5=Gwendoline|last6=Prade|first6=Nais|last7=Delabesse|first7=Eric|last8=Broccardo|first8=Cyril|last9=Dastugue|first9=Nicole|date=2011|title=Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants|url=https://www.ncbi.nlm.nih.gov/pubmed/21474671|journal=Blood|volume=117|issue=21|pages=5719–5722|doi=10.1182/blood-2011-01-333013|issn=1528-0020|pmid=21474671}}</ref>. Rearrangement of MYB/GATA1 with t(X;6)(p11;q23) has been reported in four male infants<ref name=":4" /><ref name=":5" />. The fusion gene leads to downregulation of ''MYB'', upregulation of ''GATA1'', and commits myeloid cells to the granulocyte lineage and blocks their differentiation<ref name=":4" /><ref name=":5" />. | ||
| Line 123: | Line 123: | ||
<blockquote class='blockedit'>{{Box-round|title= | <blockquote class='blockedit'>{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in: | ||
* Chromosomal Rearrangements (Gene Fusions) | * Chromosomal Rearrangements (Gene Fusions) | ||
* Individual Region Genomic Gain/Loss/LOH | * Individual Region Genomic Gain/Loss/LOH | ||
| Line 136: | Line 136: | ||
==Individual Region Genomic Gain / Loss / LOH== | ==Individual Region Genomic Gain / Loss / LOH== | ||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 146: | Line 146: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |EXAMPLE | ||
7 | 7 | ||
| | |EXAMPLE Loss | ||
| | |EXAMPLE | ||
chr7:1- 159,335,973 [hg38] | chr7:1- 159,335,973 [hg38] | ||
| | |EXAMPLE | ||
chr7 | chr7 | ||
| Line 159: | Line 159: | ||
|Yes | |Yes | ||
|No | |No | ||
| | |EXAMPLE | ||
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). | Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). | ||
|- | |- | ||
| | |EXAMPLE | ||
8 | 8 | ||
| | |EXAMPLE Gain | ||
| | |EXAMPLE | ||
chr8:1-145,138,636 [hg38] | chr8:1-145,138,636 [hg38] | ||
| | |EXAMPLE | ||
chr8 | chr8 | ||
| Line 176: | Line 176: | ||
|No | |No | ||
|No | |No | ||
| | |EXAMPLE | ||
Common recurrent secondary finding for t(8;21) (add reference). | Common recurrent secondary finding for t(8;21) (add reference). | ||
|} | |} | ||
<blockquote class='blockedit'>{{Box-round|title= | <blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}} | ||
Not applicable. | Not applicable. | ||
| Line 188: | Line 188: | ||
==Characteristic Chromosomal Patterns== | ==Characteristic Chromosomal Patterns== | ||
Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis | Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 198: | Line 198: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |EXAMPLE | ||
Co-deletion of 1p and 18q | Co-deletion of 1p and 18q | ||
| Line 204: | Line 204: | ||
|No | |No | ||
|No | |No | ||
| | |EXAMPLE: | ||
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). | See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). | ||
|} | |} | ||
<blockquote class='blockedit'>{{Box-round|title= | <blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}} | ||
A few male patients have been reported with massive hyperdiploid or tetraploid karyotypes<ref name=":1" /><ref name=":2" /><ref name=":3" /><ref>{{Cite journal|last=Kim|first=Bo Hyun|last2=Kim|first2=Hye Ryoun|last3=Lee|first3=Mi-Kyung|last4=Chi|first4=Hyunyoung|date=2013|title=Two cases of near-tetraploidy in acute leukemias of ambiguous lineage|url=https://www.ncbi.nlm.nih.gov/pubmed/24003431|journal=Annals of Laboratory Medicine|volume=33|issue=5|pages=371–374|doi=10.3343/alm.2013.33.5.371|issn=2234-3814|pmc=3756245|pmid=24003431}}</ref>. Monosomy 7 was reported in a rare case<ref>{{Cite journal|last=Shin|first=So Youn|last2=Koo|first2=Sun Hoe|last3=Kwon|first3=Kye Cheol|last4=Park|first4=Jong Woo|last5=Ko|first5=Chi Seon|last6=Jo|first6=Deog Yeon|date=2007|title=Monosomy 7 as the sole abnormality of an acute basophilic leukemia|url=https://www.ncbi.nlm.nih.gov/pubmed/17213028|journal=Cancer Genetics and Cytogenetics|volume=172|issue=2|pages=168–171|doi=10.1016/j.cancergencyto.2006.09.016|issn=0165-4608|pmid=17213028}}</ref>. | A few male patients have been reported with massive hyperdiploid or tetraploid karyotypes<ref name=":1" /><ref name=":2" /><ref name=":3" /><ref>{{Cite journal|last=Kim|first=Bo Hyun|last2=Kim|first2=Hye Ryoun|last3=Lee|first3=Mi-Kyung|last4=Chi|first4=Hyunyoung|date=2013|title=Two cases of near-tetraploidy in acute leukemias of ambiguous lineage|url=https://www.ncbi.nlm.nih.gov/pubmed/24003431|journal=Annals of Laboratory Medicine|volume=33|issue=5|pages=371–374|doi=10.3343/alm.2013.33.5.371|issn=2234-3814|pmc=3756245|pmid=24003431}}</ref>. Monosomy 7 was reported in a rare case<ref>{{Cite journal|last=Shin|first=So Youn|last2=Koo|first2=Sun Hoe|last3=Kwon|first3=Kye Cheol|last4=Park|first4=Jong Woo|last5=Ko|first5=Chi Seon|last6=Jo|first6=Deog Yeon|date=2007|title=Monosomy 7 as the sole abnormality of an acute basophilic leukemia|url=https://www.ncbi.nlm.nih.gov/pubmed/17213028|journal=Cancer Genetics and Cytogenetics|volume=172|issue=2|pages=168–171|doi=10.1016/j.cancergencyto.2006.09.016|issn=0165-4608|pmid=17213028}}</ref>. | ||
| Line 216: | Line 216: | ||
==Gene Mutations (SNV / INDEL)== | ==Gene Mutations (SNV / INDEL)== | ||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 226: | Line 226: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |EXAMPLE: TP53; Variable LOF mutations | ||
EXAMPLE: | |||
EGFR; Exon 20 mutations | EGFR; Exon 20 mutations | ||
EXAMPLE: BRAF; Activating mutations | |||
| | |EXAMPLE: TSG | ||
| | |EXAMPLE: 20% (COSMIC) | ||
EXAMPLE: 30% (add Reference) | |||
| | |EXAMPLE: IDH1 R123H | ||
| | |EXAMPLE: EGFR amplification | ||
| | | | ||
| | | | ||
| | | | ||
| | |EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference). | ||
<br /> | <br /> | ||
|} | |} | ||
| Line 248: | Line 248: | ||
<blockquote class='blockedit'>{{Box-round|title= | <blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}} | ||
Not applicable. | Not applicable. | ||
| Line 263: | Line 263: | ||
==Genes and Main Pathways Involved== | ==Genes and Main Pathways Involved== | ||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | ||
|- | |- | ||
| | |EXAMPLE: BRAF and MAP2K1; Activating mutations | ||
| | |EXAMPLE: MAPK signaling | ||
| | |EXAMPLE: Increased cell growth and proliferation | ||
|- | |- | ||
| | |EXAMPLE: CDKN2A; Inactivating mutations | ||
| | |EXAMPLE: Cell cycle regulation | ||
| | |EXAMPLE: Unregulated cell division | ||
|- | |- | ||
| | |EXAMPLE: KMT2C and ARID1A; Inactivating mutations | ||
| | |EXAMPLE: Histone modification, chromatin remodeling | ||
| | |EXAMPLE: Abnormal gene expression program | ||
|} | |} | ||
<blockquote class='blockedit'>{{Box-round|title= | <blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}} | ||
The molecular mechanism is not completely understood. | The molecular mechanism is not completely understood. | ||